Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Malaga – page 31

1 063 clinical trials in Malaga, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Malaga at a glance
1 063
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 063 trials in Malaga

Open in trial search

Prostate cancer metastatic

Recruiting

Study of talazoparib and enzalutamide combination treatment for patients with metastatic prostate cancer who previously received abiraterone

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Fundacion Oncosur

Ovarian cancer

Recruiting

Study on the Effectiveness of Niraparib Rechallenge After Surgery in Ovarian Cancer Patients with Limited Metastasis

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Niraparib Tosilate Monohydrate
  • Sponsor:Medica Scientia Innovation Research S.L.

Non-small cell lung cancer

Recruiting

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:MK-1084
  • Sponsor:Merck Sharp & Dohme LLC

Bladder transitional cell carcinoma

Recruiting

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer

Recruiting

Study of RMC-6291 and Pembrolizumab with or without Chemotherapy for Patients with Advanced KRAS G12C Mutated Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Factor VIII deficiency+3

Recruiting

Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab
  • Sponsor:Novo Nordisk A/S

Study on Datopotamab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic Endometrial, Gastric, Prostate, Ovarian, Colorectal, Urothelial, and Biliary Tract Cancers

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AstraZeneca AB

Endometrial cancer+12

Recruiting

Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Recruiting

Study of RMC-6236 and Pembrolizumab with or without Chemotherapy for Patients with RAS-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Ovarian cancer

Recruiting

Study of Paclitaxel, Carboplatin, and Bevacizumab with Niraparib for Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer After Surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Arcagy Gineco

Myasthenia gravis

Recruiting

Study on the Effects of Iptacopan in Patients with Generalized Myasthenia Gravis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Hypertrophic cardiomyopathy

Recruiting

Study on the Long-Term Safety of Aficamten (CK-3773274) for Patients with Symptomatic Hypertrophic Cardiomyopathy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aficamten
  • Sponsor:Cytokinetics Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Malaga

What the registry says about research in the country

01 Autoimmune Conditions

Research focusing on innovative treatments for cutaneous lupus erythematosus and myasthenia gravis, evaluating new therapeutic approaches to improve patient outcomes.

  • Lupus skin manifestations
  • Neuromuscular disorders
  • Chronic urticaria management

Studies aim to assess novel therapies' effectiveness in reducing disease activity and improving daily living activities.

02 Infectious Diseases

Innovative vaccine development studies targeting COVID-19, cytomegalovirus, and respiratory syncytial virus, focusing on prevention and immune response.

  • Viral infections
  • Vaccine combinations
  • Pediatric prevention

Research emphasizes safety and immunogenicity in various population groups.

03 Oncology

Advanced studies in bladder cancer, colorectal cancer, and gastric cancer, evaluating targeted therapies and combination treatments.

  • Non-muscle invasive treatments
  • Metastatic disease management
  • Immunotherapy approaches

Trials focus on improving survival rates and treatment responses in various cancer types.

04 Respiratory Medicine

Research examining new treatments for chronic rhinosinusitis and COPD, with emphasis on symptom management and exacerbation prevention.

  • Airway inflammation
  • Pulmonary function
  • Quality of life measures

Studies evaluate novel therapeutic approaches for chronic respiratory conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.